Keyword search (3,171 papers available)


Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Author(s): Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Trembla...

Can J Cardiol. 2016 05;32(5):569-88 Authors: Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean...

Article GUID: 27118291
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

Author(s): Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cli...

Can J Cardiol. 2017 05;33(5):557-576 Authors: Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Mil...

Article GUID: 28449828
Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.

Author(s): Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, B...

Can J Cardiol. 2018 05;34(5):506-525 Authors: Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tr...

Article GUID: 29731013
Title:Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.
Authors:Leung AA,  Nerenberg K,  Daskalopoulou SS,  McBrien K,  Zarnke KB,  Dasgupta K,  Cloutier L,  Gelfer M,  Lamarre-Cliche M,  Milot A,  Bolli P,  Tremblay G,  McLean D,  Tobe SW,  Ruzicka M,  Burns KD,  Vallée M,  Prasad GV,  Lebel M,  Feldman RD,  Selby P,  Pipe A,  Schiffrin EL,  McFarlane PA,  Oh P,  Hegele RA,  Khara M,  Wilson TW,  Penner SB,  Burgess E,  Herman RJ,  Bacon SL,  Rabkin SW,  Gilbert RE,  Campbell TS,  Grover S,  Honos G,  Lindsay P,  Hill MD,  Coutts SB,  Gubitz G,  Campbell NR,  Moe GW,  Howlett JG,  Boulanger JM,  Prebtani A,  Laroc
Link:https://www.ncbi.nlm.nih.gov/pubmed/27118291?dopt=Abstract
Category:Can J Cardiol
PMID:27118291
Dept Affiliation: HKAP
1 Division of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: aacleung@ucalgary.ca.
2 Department of Medicine and Department of Obstetrics and Gynecology, University of Calgary, Calgary, Alberta, Canada.
3 Divisions of General Internal Medicine, Clinical Epidemiology and Endocrinology, Department of Medicine, McGill University, McGill University Health Centre, Montreal, Quebec, Canada.
4 Departments of Family Medicine and Community Health Sciences, Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
5 Division of General Internal Medicine, University of Calgary, Calgary, Alberta, Canada.
6 Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, Canada.
7 Department of Family Medicine, University of British Columbia, Copeman Healthcare Centre, Vancouver, British Columbia, Canada.
8 Institut de Recherches Cliniques de Montréal, Université de Montréal, Montréal, Quebec, Canada.
9 Department of Medicine, Université Laval, Québec, Quebec, Canada.
10 Ambulatory Internal Medicine Teaching Clinic, St Catharines, Ontario, Canada.
11 CHU-Québec-Hopital St Sacrement, Québec, Quebec, Canada.
12 University of Alberta, Edmonton, Alberta, Canada.
13 University of Toronto, Toronto, Ontario, Canada.
14 Division of Nephrology, Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
15 Hôpital Maisonneuve-Rosemont, Université de Montréal, Montréal, Quebec, Canada.
16 Discipline of Medicine, Memorial University of Newfoundland, St John's, Newfoundland and Labrador, Canada.
17 Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada.
18 University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
19 Department of Medicine and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
20 Division of Nephrology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
21 University Health Network, University of Toronto, Toronto, Ontario, Canada.
22 Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University, London, Ontario, Canada.
23 Vancouver Coastal Health Addiction Services, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
24 Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
25 Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
26 Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
27 Department of Exercise Science, Concordia University, and Montreal Behavioural Medicine Centre, Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada.
28 Vancouver Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
29 Division of Endocrinology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
30 Department of Psychology, University of Calgary, Calgary, Alberta, Canada.
31 Division of Clinical Epidemiology, Montreal General Hospital, Montreal, Quebec, Canada.
32 University of Montreal, Montreal, Quebec, Canada.
33 Best Practices and Performance, Heart and Stroke F

Description:

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Can J Cardiol. 2016 05;32(5):569-88

Authors: Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM, CHEP Guidelines Task Force

Abstract

Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, and treatment of hypertension. This year, we present 4 new recommendations, as well as revisions to 2 previous recommendations. In the diagnosis and assessment of hypertension, automated office blood pressure, taken without patient-health provider interaction, is now recommended as the preferred method of measuring in-office blood pressure. Also, although a serum lipid panel remains part of the routine laboratory testing for patients with hypertension, fasting and nonfasting collections are now considered acceptable. For individuals with secondary hypertension arising from primary hyperaldosteronism, adrenal vein sampling is recommended for those who are candidates for potential adrenalectomy. With respect to the treatment of hypertension, a new recommendation that has been added is for increasing dietary potassium to reduce blood pressure in those who are not at high risk for hyperkalemia. Furthermore, in selected high-risk patients, intensive blood pressure reduction to a target systolic blood pressure = 120 mm Hg should be considered to decrease the risk of cardiovascular events. Finally, in hypertensive individuals with uncomplicated, stable angina pectoris, either a ß-blocker or calcium channel blocker may be considered for initial therapy. The specific evidence and rationale underlying each of these recommendations are discussed. Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force will continue to provide annual updates.

PMID: 27118291 [PubMed - indexed for MEDLINE]